Moonbeam Begins GLMR Migration to Base Before July 31
- Moonbeam launched the GLMR migration with a July 31, 2026 bridge deadline.
- GLMR will become a native ERC-20 token on Base through a 1:1 swap.
- Moonbeam introduced a decentralized AI agent protocol alongside the network transition.
Moonbeam (GLMR) migration to Base has officially begun, marking a significant change for the Ethereum-compatible network. The project confirmed that GLMR holders can now bridge tokens through the official portal before the July 31, 2026 deadline. The move also introduces the new Moonbeam Protocol, designed for decentralized AI agent communication and on-chain settlement.
Moonbeam GLMR Migration Introduces New AI Focus
The Moonbeam GLMR migration will convert GLMR into a native ERC-20 token on Base through a 1:1 swap. According to the project, users who complete the migration will maintain their participation in the protocol after the transition.
Moonbeam said the move represents a strategic shift away from its long-standing role within the Polkadot ecosystem. The network plans to gradually wind down its existing blockchain while expanding its presence on Base.
Alongside the migration, Moonbeam unveiled the Moonbeam Protocol, a decentralized infrastructure that enables AI agents to discover services, negotiate tasks, and settle payments using verifiable on-chain proofs.
Moonbeam GLMR Migration Requires Action Before July 31
The Moonbeam GLMR migration requires self-custody holders to bridge their tokens before the July 31 deadline using the project’s official migration portal. Users holding GLMR on centralized exchanges generally do not need to take action, although they should monitor exchange announcements for migration timelines.
The team also advised users to withdraw assets locked in staking, lending markets, liquidity pools, or other DeFi applications before bridging. Any remaining assets on the Moonbeam chain could become inaccessible after the network eventually ceases operations.
Nova Wallet issued a similar reminder, urging holders with GLMR or other assets such as DOT and stablecoins on Moonbeam or connected parachains to transfer funds before the deadline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
